Hydroxychloroquine with or without Macrolide and Standard of Care versus Standard of Care Alone for COVID-19 Cases: A Systematic Review and Meta-Analysis
Hydroxychloroquine for COVID-19
Abstract
Background: The specific treatment has not yet been approved for the therapy of COVID-19 pandemic. In this review, we aimed at assessing the role of hydroxychloroquine with/without macrolide in terms of efficacy and adverse effects against the standard of care (SOC).
Methods: PubMed, Medline, Google Scholar, Cochrane Library, and Clinicaltrials.gov were searched for the quantitative and qualitative synthesis of 13 studies using PRISMA guidelines. Assessment of heterogeneity was done using I-squared (I2) test and fixed/random effect analysis was done to determine the odds/risk ratio among selected studies.
Results: Our study demonstrated no significant differences in improvement for virological cure (RR 0.95, 0.67-1.34), whereas a significant relationship was there in radiological progression (RR 1.40, 1.03-1.91) between the two arms. There are 1.52 times the odds of intubation during treatment (CI 0.61-3.77), 1.08 times the risk of mortality (CI 0.65-1.79), and about 2.21 times increased risk of development of adverse effect (OR 2.21, 0.95-5.17). Among randomized controlled trials, the treatment group has 3.5 times (OR 3.48, 1.64-7.42) higher risk of developing adverse effects. There is 2.5 times the likelihood of severe arrhythmias and QT prolongation (OR 2.49, 1.67-3.70) on the treatment arm compared to control.
Conclusions: Hydroxychloroquine with/without macrolide demonstrated no beneficial effect in viral clearance and survival rates while showed significant relation in radiological improvement compared to SOC. The increased risk of intubation, overall side effects, and cardiac complications like arrhythmias and QT prolongation suggests utilizing such treatment to be judged with clinical relevance and proper monitoring.
References
Khadka S, Hashmi FK, Usman M. Preventing COVID-19 in low- and middle-income countries. Drugs Ther Perspect. 2020;
Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 2020;(0).
Khadka S, Yuchi A, Shrestha D, Budhathoki P, Al-Subari S, Alhouzani T, et al. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic. Altern Ther Health Med. 2020;AT6513.
Garcia‐Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. Optimizing hydroxychloroquine dosing for patients with COVID‐19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020;
Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg. 2020;tpmd200290.
Catalano R, Rocca R, Juli G, Costa G, Maruca A, Artese A, et al. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. Eur J Med Chem. 2019;183:111715.
Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020;102569.
Aggarwal G, Henry BM, Aggarwal S, Bangalore S. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. Am J Cardiol. 2020;
Bessière F, Roccia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT Intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020;
Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. JAMA Cardiol. 2020;
Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies. 2020;
Dai Y, Lin G, Shi D. Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. Clin Ther. 2020;
Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, et al. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. J Rheumatol. 2020;
Al‐Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID‐19; the desperate search for effectiveness. Clin Pharmacol Ther. 2020;
Liberati A, Altman DG, Tetzlaff J, Mulrow C. G?? tzsche, PC, Ioannidis, JPA,… Moher, D.(2009). The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 62(10):e1-34.
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;
Study Quality Assessment Tools [Internet]. National Heart, Lung, and Blood Institute (NHLBI). 2020 [cited 2020 Aug 1]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. Jama. 2020;
Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. Prepr posted April. 2020;23.
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;
Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. bmj. 2020;369.
Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv. 2020;
de Novales FJM, Ramírez-Olivencia G, Estébanez M, de Dios B, Herrero MD, Mata T, et al. Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. 2020;
Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;1.
Lee JE, Lee SO, Heo J, Kim DW, Park MR, Son H, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of coronavirus disease 2019 with mild to moderate severity. Preprint.
Barbosa J, Kaitis D, Freedman R, Le K, Lin X. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19-a quasi-randomized comparative study. Bibliovid.[cited 2020 Apr 15]. 2020.
Chen J, LIU D, LIU L, LIU P, XU Q, XIA L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Medical Sci. 2020;49(1):0.
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020;
Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. bmj. 2020;369.
ClinicalTrials.gov [Internet]. NIH U.S. National Library of Medicine. 2020. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID+19&term=Hydroxychloroquine&cntry=&state=&city=&dist=&Search=Search
Singh AK, Singh A, Singh R, Misra A. Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;
Chacko J, Brar G, Premkumar R. Hydroxychloroquine in COVID-19: A systematic review and meta-analysis. medRxiv. 2020;
Ren L, Xu W, Overton JL, Yu S, Chiamvimonvat N, Thai PN. Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. medRxiv. 2020;
Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: a systematic review and meta‐analysis. J Med Virol. 2020;
Copyright (c) 2021 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in EJMS are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). The author(s) as the copyright holder will retain the ownership of the copyrights without any restrictions for their content under the CC-BY 4.0 license, and allow others to copy, use, print, share, modify, and distribute the content of the article even in commercial purpose as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers. Appropriate attribution can be provided by simply citing the original article.
On behalf of all the authors, the corresponding author is responsible for completing and returning the agreement form to the editorial office. More information about the terms and conditions, privacy policies, and copyrights can be found on the webpage of the Creative Commons license privacy policy. https://creativecommons.org/licenses/by/4.0/
